ArticleAntimicrobial agents and chemotherapy2019
What's Old Is New Again: Bacteriophage Therapy in the 21st Century.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Current Clinical Laboratory Challenges to Widespread Adoption of Phage Therapy in the United States.Antibiotics (Basel, Switzerland) · 2025Review
- Phage Milagro: a platform for engineering a broad host range virulent phage forJournal of virology · 2023Article
- Safety Properties ofFoods (Basel, Switzerland) · 2023Review
- Application of Phage Therapy in a Case of a Chronic Hip-Prosthetic Joint Infection due toOpen forum infectious diseases · 2023Article
- Phage therapeutics: from promises to practices and prospectives.Applied microbiology and biotechnology · 2021Review
- Preclinical data and safety assessment of phage therapy in humans.Current opinion in biotechnology · 2021Review
- Bacteriophage Cocktails Protect Dairy Cows Against Mastitis Caused By Drug ResistantFrontiers in cellular and infection microbiology · 2021Article
- Phage Therapy: Towards a Successful Clinical Trial.Antibiotics (Basel, Switzerland) · 2020Article
- Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States.Open forum infectious diseases · 2020Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We highlight features associated with bacteriophage therapy that make it an attractive treatment option for multidrug-resistant infections and also discuss some of the challenges that need to be considered in the design and execution of clinical trials directed at evaluating the efficacy of bacteriophage therapy in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.